Patient characteristics before ibrutinib
| Characteristics . | Number . | Range, %, or 95% CI . |
|---|---|---|
| All | 114 | |
| Median Age | 68 y | 46-85 |
| Median prior systemic therapies | 3 | 0-10 |
| Prior rituximab | 108 | 95% |
| Prior alkylator | 105 | 92% |
| Prior anthracycline | 71 | 62% |
| Prior bendamustine | 59 | 52% |
| Prior bortezomib | 53 | 46% |
| Prior cytarabine | 38 | 33% |
| Prior lenalidomide | 20 | 18% |
| Prior stem cell transplant (autologous/allogeneic) | 18/6 | 16%/5% |
| MIPI scores at start of ibrutinib | ||
| High risk | 46 | 39% |
| Intermediate risk | 35 | 26% |
| Low risk | 22 | 19% |
| Ki67 > 30% | 34/47 | 72% |
| Response to ibrutinib | ||
| CR | 13 | 11% |
| Partial response | 45 | 39% |
| Stable disease | 5 | 4% |
| Progressive disease | 37 | 32% |
| Not reported/not evaluable | 14 | 12% |
| Duration of ibrutinib | 4.7 mo | 95% CI, 3.8-5.7 0.7-43.6 |
| Characteristics . | Number . | Range, %, or 95% CI . |
|---|---|---|
| All | 114 | |
| Median Age | 68 y | 46-85 |
| Median prior systemic therapies | 3 | 0-10 |
| Prior rituximab | 108 | 95% |
| Prior alkylator | 105 | 92% |
| Prior anthracycline | 71 | 62% |
| Prior bendamustine | 59 | 52% |
| Prior bortezomib | 53 | 46% |
| Prior cytarabine | 38 | 33% |
| Prior lenalidomide | 20 | 18% |
| Prior stem cell transplant (autologous/allogeneic) | 18/6 | 16%/5% |
| MIPI scores at start of ibrutinib | ||
| High risk | 46 | 39% |
| Intermediate risk | 35 | 26% |
| Low risk | 22 | 19% |
| Ki67 > 30% | 34/47 | 72% |
| Response to ibrutinib | ||
| CR | 13 | 11% |
| Partial response | 45 | 39% |
| Stable disease | 5 | 4% |
| Progressive disease | 37 | 32% |
| Not reported/not evaluable | 14 | 12% |
| Duration of ibrutinib | 4.7 mo | 95% CI, 3.8-5.7 0.7-43.6 |
MIPI, Mantle Cell Lymphoma International Prognostic Index.